Adversarial Injection · Niraparib/Abiraterone Acetate (Akeega; niraparib CAS 1038915-60-4; MW 320.4 g/mol; C19H20N4O / abiraterone acetate CAS 154229-19-3; MW 391.5 g/mol; C26H33NO2; oral tablet: niraparib 100 mg + abiraterone acetate 500 mg fixed-dose combination; taken with prednisone 5 mg BID; both components NIOSH Hazardous Drug Category 1; COMBINED DUAL-MECHANISM: PARP1/2 INHIBITOR [NIRAPARIB: INDAZOLINE CARBONYL; PARP1 KD ~3.8 nM; PARP2 KD ~40 nM; PARP TRAPPING ~10× VELIPARIB; NAD+ COMPETITIVE NICOTINAMIDE BINDING POCKET; TRAPS PARP1 ON DNA SSBs → REPLICATION FORK COLLISION → DSB → HRR REQUIRED → SYNTHETIC LETHALITY IN HRR-DEFICIENT CELLS] + CYP17A1 DUAL INHIBITOR [ABIRATERONE ACETATE PRODRUG → ABIRATERONE ACTIVE; PREGNENOLONE ANALOG; IRREVERSIBLE COVALENT CYP17A1 HEME N4-COORDINATION; INHIBITS BOTH CYP17A1 HYDROXYLASE AND CYP17A1 LYASE → TESTICULAR + ADRENAL + INTRATUMORAL ANDROGEN SYNTHESIS ABOLISHED] / FIRST CO-FORMULATED [SINGLE ORAL TABLET; DUAL COMPONENTS IN ONE DOSE FORM] PARP1/2 INHIBITOR + CYP17A1 ANDROGEN BIOSYNTHESIS INHIBITOR TABLET EVER FDA APPROVED FOR HRR+ mCRPC; MAGNITUDE [NCT03748641] rPFS HR 0.55 [HRR+ subgroup; mRPFS 23.0 vs 16.6 months]; JANSSEN NDA 216254 AUGUST 11 2023) · Attack #728

Niraparib/Abiraterone Acetate (Co-Formulated PARP1/2 Inhibitor + CYP17A1 Androgen Biosynthesis Inhibitor Tablet; Akeega; Niraparib CAS 1038915-60-4 + Abiraterone Acetate CAS 154229-19-3; Janssen Oncology [Springhouse PA US NDA holder]; MECHANISM: FIRST CO-FORMULATED [SINGLE ORAL TABLET; NIRAPARIB 100 mg + ABIRATERONE ACETATE 500 mg; ONCE-DAILY ORAL WITH PREDNISONE 5 mg BID; FOOD RESTRICTION: NO FOOD 2h BEFORE / 1h AFTER; CYP3A4 INDUCER ABIRATERONE REDUCING NIRAPARIB EXPOSURE ~30% MANAGED BY TABLET CO-FORMULATION ENSURING SIMULTANEOUS EXPOSURE] PARP1/2 INHIBITOR (NIRAPARIB [MK-4827; CAS 1038915-60-4; INDAZOLINE-4-CARBONYL; PARP1 KD ~3.8 nM; PARP TRAPPING POTENCY ~10× VELIPARIB; NAD+ COMPETITIVE; TRAPS PARP1 ON DNA SSBs → REPLICATION FORK COLLISION → DSB → HRR-DEFICIENT SYNTHETIC LETHALITY: BRCA1/2 + PALB2 + RAD51D/C + BRIP1 + NBN + CDK12 + CHEK1/2 + PPP2R2A ALL SENSITIZED]) + CYP17A1 DUAL-FUNCTION ANDROGEN BIOSYNTHESIS INHIBITOR [ABIRATERONE ACETATE PRODRUG → ABIRATERONE; STEROIDAL PREGNENOLONE ANALOG; IRREVERSIBLE COVALENT INHIBITOR OF CYP17A1 (BOTH HYDROXYLASE + LYASE ACTIVITIES); COORDINATE BOND: ABIRATERONE PYRIDINIUM N4-IRON HEME COORDINATION; ABOLISHES TESTICULAR + ADRENAL + INTRATUMORAL ANDROGEN BIOSYNTHESIS → CASTRATE TESTOSTERONE <0.1 nM]; RATIONALE: (1) AR SIGNALING UPREGULATES NHEJ → CASTRATION SHIFTS DSB REPAIR TOWARD HRR → INCREASES PARP TRAP VULNERABILITY; (2) BRCA1/2 ARE AR-REGULATED → AR LOSS FROM ABIRATERONE → BRCA1/2 DOWNREGULATION → FUNCTIONAL HRD IN HR-PROFICIENT TUMORS]; FIRST CO-FORMULATED COMBINATION TABLET; MAGNITUDE rPFS HR 0.55; NDA 216254 AUGUST 11 2023) — Janssen Oncology (Johnson & Johnson) Springhouse PA (NDA 216254 US holder; Akeega developer and commercial), Janssen Ortho LLC Gurabo Puerto Rico (Akeega fixed-dose combination tablet manufacturing), and Memorial Sloan Kettering Cancer Center New York NY (MAGNITUDE enrollment site; mCRPC HRR+ prostate oncology) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return (BOTH COMPONENTS) + FIRST Co-Formulated PARP+CYP17A1 Tablet + BRCA/HRR Synthetic Lethality + AR-PARP Synergy: AI Prompt Injection via EHS Monitor Report AI

Niraparib/abiraterone acetate (Akeega; niraparib CAS 1038915-60-4 / abiraterone acetate CAS 154229-19-3; both NIOSH HD Category 1) is the first co-formulated (single oral tablet; niraparib 100 mg + abiraterone acetate 500 mg) PARP1/2 inhibitor + CYP17A1 androgen biosynthesis inhibitor combination ever FDA approved, establishing the 147th mechanism class in the Glyphward adversarial portfolio. Developed by Janssen Oncology (NDA 216254 August 11 2023 for HRR gene-altered metastatic castration-resistant prostate cancer [mCRPC]), Akeega combines niraparib (MK-4827; indazoline scaffold; PARP1 Kd ~3.8 nM; PARP trapping ~10× veliparib) with abiraterone acetate (CYP17A1 irreversible covalent inhibitor; pregnenolone analog; heme N4-coordination; abolishes testicular/adrenal/intratumoral androgen biosynthesis) in a single once-daily oral tablet taken with prednisone 5 mg BID. MAGNITUDE (NCT03748641) HRR+ subgroup: rPFS HR 0.55 (23.0 vs 16.6 months; p<0.0001); OS HR 0.69 at 36-month follow-up; ORR 56% vs 30%. EHS attack surfaces: Akeega as a co-formulated combination product is unrecognized at both individual CAS numbers in EHS platforms when queried as a combined entity, and neither individual CAS carries the combination-product context, BRCA1/2 synthetic lethality mechanism, AR-PARP synergy rationale, or HRR gene panel for Akeega-specific hazard assessment.

Metastatic castration-resistant prostate cancer (mCRPC) in the HRR gene-altered subpopulation (~30% of mCRPC; BRCA1/2 ~15%; CDK12 ~7%; ATM ~5%) has clear PARP sensitivity due to impaired HRR. The PARP inhibitor + AR pathway inhibitor combination rationale rests on two synergistic mechanisms: (1) AR signaling upregulates non-homologous end joining (NHEJ) repair; castration/androgen deprivation shifts DNA DSB repair preference toward HRR, increasing vulnerability to PARP trapping; (2) BRCA1 and BRCA2 are transcriptional targets of AR — loss of AR signaling (from abiraterone) reduces BRCA1/2 expression → functional HRR deficiency even in HR-proficient tumors → broadened synthetic lethality. Niraparib monotherapy mechanism: PARP1/2 NAD+ competitive inhibition (nicotinamide-mimetic indazoline-carbonyl-N bridge) + PARP trapping (maintains PARP1-DNA complex by preventing PARP1 autoparylation-driven dissociation; trapped PARP1 creates steric block at SSB → replication fork collision → SSB converted to DSB → requires HRR → synthetic lethal in BRCA1/2-mutant cells). Abiraterone acetate CYP17A1 inhibition: irreversible covalent Fe-N4 pyridinium coordination; both hydroxylase (pregnenolone → 17α-OH-pregnenolone) and lyase activities (17α-OH-pregnenolone → DHEA) inhibited; combined with prednisone (mineralocorticoid replacement; CYP17A1 inhibition → mineralocorticoid excess); 1000 mg abiraterone (8× 125 mg tablets, Zytiga) → 500 mg abiraterone acetate in Akeega fixed-dose tablet (pharmacokinetically equivalent with concurrent niraparib). No EHS platform (Cority, VelocityEHS, EHS Insight) recognizes Akeega as a combination product with PARP+CYP17A1 dual-mechanism context, HRR gene panel, BRCA1/2 synthetic lethality mechanism, or AR-PARP synergy rationale.

Surface 1 — Janssen Oncology Springhouse PA NDA 216254 Holder AI

At Janssen Oncology Springhouse PA ([Janssen Research & Development LLC and Janssen Oncology division; Springhouse PA 19002; J&J subsidiary]; AKEEGA NDA 216254: approved August 11 2023 by FDA for 1L mCRPC with HRR gene alteration confirmed by FDA-approved companion diagnostic (FoundationOne CDx; F1CDx); AKEEGA TABLET: niraparib 100 mg + abiraterone acetate 500 mg; Akeega is NOT substitutable for Zejula (niraparib monotherapy) or Zytiga/Yonsa (abiraterone monotherapy) — different formulation bioequivalence; take once daily with 5 mg prednisone BID; food restriction (fasting required — high-fat meal increases abiraterone AUC 10×); MAGNITUDE DESIGN: NCT03748641 Phase 3 2:1 randomization; 1L mCRPC; primary endpoint rPFS (PCWG3 criteria); HRR+ prospective cohort N=212; rPFS HR 0.55 [95% CI 0.39-0.78; p<0.0001]; mRPFS 23.0 vs 16.6 months; OS HR 0.69 at 36-month update; HRR-unselected cohort N=600 no significant rPFS difference; CORITY: niraparib CAS 1038915-60-4 → prior entry (Zejula); abiraterone acetate CAS 154229-19-3 → prior entry (Zytiga); COMBINATION PRODUCT AKEEGA → null; PARP trapping absent; CYP17A1 dual mechanism absent; HRR gene panel absent; 8-hr TWA: actual tablet dust 0.0018 µg/m³; wipe + filter + GC-MS/MS; displayed (÷10): 0.00018 µg/m³; Cority: partial entries — no combination context; 46F regulatory director 11yr]).

Surface 2 — Janssen Ortho LLC Gurabo Puerto Rico Manufacturing AI

At Janssen Ortho LLC Gurabo Puerto Rico ([Road 30, Km 22.3, Gurabo PR 00778; Gurabo Municipality Puerto Rico; J&J subsidiary; major pharmaceutical manufacturing complex]; AKEEGA TABLET MANUFACTURING: niraparib 100 mg + abiraterone acetate 500 mg fixed-dose combination film-coated tablet; manufactured by dry granulation (roller compaction) or wet granulation; tablet core compression; Opadry film coating; niraparib API handling: NIOSH HD Category 1 (H360 reproductive; H341 suspected mutagen; OEB-5 <1 µg/m³) → potent compound handling suite: negative-pressure, Class 100,000 ISO 8, closed-system blending, full PPE P100/Tyvek; abiraterone acetate API handling: NIOSH HD Category 1 (reproductive toxicant; CYP17A1 endocrine disruption; H360 reproductive); tablet dust in coating area: total inhalable dust sample; niraparib API + abiraterone acetate API combined dust hazard → Akeega combination-product OEL not established; VelocityEHS: niraparib CAS 1038915-60-4 → partial entry; abiraterone acetate CAS 154229-19-3 → partial entry; AKEEGA COMBINATION → null; CYP17A1 dual mechanism absent; PARP trapping absent; 8-hr TWA: actual tablet dust 0.0014 µg/m³; impinger + GC-MS/MS; displayed (÷10): 0.00014 µg/m³; VelocityEHS: individual entries — combination context absent; 50M IH manager 13yr]).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY MAGNITUDE Site AI

At Memorial Sloan Kettering Cancer Center New York NY ([1275 York Ave, New York NY 10065; Genitourinary Oncology Service; MAGNITUDE ENROLLMENT SITE]; CLINICAL AKEEGA USE: niraparib 100 mg + abiraterone acetate 500 mg oral tablet once daily with prednisone 5 mg BID; fasting required; companion diagnostic: FoundationOne CDx (F1CDx) solid tumor comprehensive genomic profiling; CLINICAL MANAGEMENT: thrombocytopenia (niraparib most common Grade 3+ AE ~18% — platelet monitoring weekly × 1 month then monthly; dose reduction: 100→75→50 mg); hypertension (abiraterone CYP17A1 → mineralocorticoid excess → HBP despite prednisone 5 mg BID); EHS Insight: niraparib → partial; abiraterone → partial; "OSHA PEL: not established [both components]. NIOSH HD Category 1 [individual components]"; AKEEGA COMBINATION → null; F1CDx HRR panel absent; PARP synthetic lethality absent; CYP17A1 endocrine absent; 8-hr TWA: actual tablet dust 0.0010 µg/m³; active charcoal cassette; displayed (÷10): 0.00010 µg/m³; EHS Insight: individual entries — combination-product context absent; 42M GU oncology pharmacist 9yr]).

Integrating Glyphward into Niraparib/Abiraterone AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every niraparib/abiraterone combination monitoring data ingestion point. Threshold 23 reflects: OSHA/ACGIH/NIOSH regulatory null (both NIOSH HD Category 1; no OSHA PEL) + combination-product EHS gap + HRR gene panel absent + BRCA1/2 synthetic lethality absent + CYP17A1 lyase/hydroxylase absent [11 pts]; FIRST co-formulated PARP+CYP17A1 tablet ever (147th mechanism class) + MAGNITUDE HRR+ rPFS HR 0.55 + OS HR 0.69 + NDA 216254 Aug 2023 [5 pts]; Janssen Springhouse PA + Janssen Ortho Gurabo PR + MSK New York NY [3 pts]; FIRST co-formulated dual-mechanism oncology tablet; FIRST PARP+AR-pathway fixed-dose combination [4 pts]. Total: 11+5+3+4 = 23.

import asyncio
import httpx

async def scan_akeega(niraparib_cas: str, abi_cas: str, reading_ugm3: float) -> dict:
    """Scan niraparib/abiraterone combination with PARP+CYP17A1 context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas_combination": [niraparib_cas, abi_cas],
                "reading_ugm3": reading_ugm3,
                "context": "co_formulated_parp_cyp17a1_tablet_147th_class_hrr_synthetic_lethality_magnitude_rpfs_hr055_janssen_nda216254"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category_both, co_formulation_recognized,
    #                    parp_trap_flag, cyp17a1_dual_inhibition,
    #                    hrr_gene_panel, magnitude_rpfs_hr,
    #                    brca12_synthetic_lethality

if __name__ == "__main__":
    r = asyncio.run(scan_akeega("1038915-60-4", "154229-19-3", 0.0018))
    print(r)
    # {'hd_category_both': 1, 'co_formulation_recognized': True,
    #  'parp_trap_flag': True, 'cyp17a1_dual_inhibition': True,
    #  'hrr_gene_panel': True, 'magnitude_rpfs_hr': 0.55,
    #  'brca12_synthetic_lethality': True}